What is CryoSurgery?
CryoSurgery operates at the intersection of medical technology and dermatology, providing professional-grade cryosurgical instruments that serve as a viable, cost-effective alternative to traditional liquid nitrogen methods. Their flagship product line, including the widely recognized Verruca-Freeze, is engineered to facilitate the safe and efficient removal of warts and various skin lesions. By democratizing access to high-quality cryotherapy, the company has successfully extended its reach beyond traditional dermatology clinics, establishing a robust presence in general practice and veterinary medicine globally. Their commitment to innovation ensures that practitioners have access to reliable, portable, and precise tools that meet rigorous clinical standards.
How much funding has CryoSurgery raised?
CryoSurgery has raised a total of $15K across 1 funding round:
Debt
$15K
Debt (2021): $15K with participation from PPP
Key Investors in CryoSurgery
PPP
Public-Private Partnership
What's next for CryoSurgery?
With the recent infusion of capital, CryoSurgery is well-positioned to accelerate its strategic growth initiatives. The company is expected to focus on scaling its distribution networks and enhancing its product development pipeline to address emerging needs in the dermatological and veterinary markets. As the firm transitions through its current growth stage, the emphasis will likely remain on operational efficiency and expanding its global footprint. By maintaining its focus on accessible, high-performance cryosurgical technology, CryoSurgery is poised to capture additional market share and drive long-term value for its stakeholders in the evolving healthcare landscape.
See full CryoSurgery company page
